We are live on ! Find out more
KL

KCK Ltd Portfolio holdings

AUM $15.1M
1-Year Est. Return 30.14%
This Fund
S&P 500
This Quarter Est. Return
+77.48%
1 Year Est. Return
+30.14%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$70.4M
AUM Growth
+$6.6M
Cap. Flow
-$28.2K
Cap. Flow %
-0.04%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SGHT icon
Sight Sciences
SGHT
+$28.2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NPCE icon
1
Neuropace
NPCE
$439M
$54.7M 77.7%
5,621,111
SGHT icon
2
Sight Sciences
SGHT
$286M
$15.7M 22.25%
4,646,866
-4,299
-0.1% -$28.2K
RNTX
3
Rein Therapeutics
RNTX
$63.1M
$34K 0.05%
22,341

Similar funds

KCK Ltd's Q3 2023 Portfolio in Review

As of Q3 2023, KCK Ltd held 3 positions worth $70.4M, up 10% from $63.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 0%. KCK Ltd opened no new positions and made no exits, leaving the 3-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • KCK Ltd's biggest Q3 2023 reduction was Sight Sciences, cutting an estimated $28.2K.
  • KCK Ltd's ten largest holdings make up 100% of its $70.4M portfolio in Q3 2023.
  • KCK Ltd opened 0 new positions and closed 0 in Q3 2023.
  • KCK Ltd's portfolio value rose 10% quarter-over-quarter to $70.4M.

Based on KCK Ltd's 13F filing for Q3 2023, filed 1 Nov 2023.